Open AccessComparison between 1-week and 1-month results of intravitreal ranibizumab in diabetic macular edema
Author(s) -
Mohsen A Abou Shousha
Publication year - 2015
Publication title -
journal of egyptian ophthalmological society
Language(s) - English
Resource type - Journals
eISSN - 2314-6648
pISSN - 2090-0686
DOI - 10.4103/2090-0686.174687
Subject(s) - medicine , ranibizumab , ophthalmology , diabetic macular edema , visual acuity , macular edema , fluorescein angiography , diabetic retinopathy , edema , optical coherence tomography , surgery , bevacizumab , diabetes mellitus , chemotherapy , endocrinology
PurposeThe aim of the present study was to compare the results of intravitreal ranibizumab in diabetic macular edema (DME) at 1-week and 1-month duration.Patients and methodsThe study included 34 eyes of 20 type II diabetic patients with DME fulfilling one or more of the following criteria: spongiform edema with central macular thickness (CMT) more than 350 μm; single or multiple cysts; or the area of sensory retinal detachment affecting the foveal center regardless of the CMT. The included eyes were subjected preoperatively to full ophthalmic examination, fluorescein angiography, and macular optical coherence tomography (OCT) using 512 by 128 cube macular scan protocol of Cirrus HD spectral domain OCT version 6. Intravitreal injection of 0.5 mg ranibizumab was administered. Follow-up, regarding the best-corrected visual acuity (BCVA) and the CMT, was scheduled at 1 week and 1 month.ResultsThe mean log MAR BCVA at baseline was 0.7 ± 0.4. One week after injection the mean of log Mar BCVA improved to be 0.6 ± 0.4. One month after injection the mean log Mar BCVA improved to be 0.5 ± 0.4. The difference between BCVA of the included eyes at baseline and that at 1 week after injection was statistically significant (P = 0.012). However, the difference between the BCVA of the included eyes at 1 week and that at 1 month after injection was not statistically significant (P = 0.361). The mean of CMT at baseline was 367.4 ± 107.6 μm, which decreased at 1 week to 325 ± 86.1 μm and at 1 month to 321 ± 96.8 μm. The difference between the CMT of the included eyes at baseline and that at 1 week after injection was statistically significant (P = 0.025). However, the difference between the CMT of the included eyes at 1 week and that at 1 month after injection was not statistically significant (P = 0.816).ConclusionIntravitreal injection of ranibizumab for DME showed significant improvement at 1 week and 1 month after injection as regards the BCVA and the CMT. However, there was no statistically significant difference in these two parameters between 1 week and 1 month after injection